GL
TBPH icon

Gerber LLC’s Theravance Biopharma TBPH Stock Holding History

Gerber LLC’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,000
Closed -$94.1K – 99
2024
Q4 		$94.1K Hold
10,000
– – 0.07% 90
2024
Q3 		$80.6K Hold
10,000
– – 0.06% 90
2024
Q2 		$84.8K Hold
10,000
– – 0.07% 88
2024
Q1 		$89.7K Hold
10,000
– – 0.08% 96
2023
Q4 		$112K Buy
+10,000
New +$101K 0.1% 88

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Gerber LLC's TBPH Position: Q1 2025 in Review

Gerber LLC sold out of Theravance Biopharma (TBPH) in Q1 2025, closing a stake of 10,000 shares — an estimated $94.1K sold.

Gerber LLC first reported a position in TBPH in Q4 2023 and held it in 5 quarters. The position peaked at $112K in Q4 2023. 131 funds tracked by Wall St. Rank hold TBPH as of Q1 2025.

  • Gerber LLC reported no remaining Theravance Biopharma position as of Q1 2025 after selling out during the quarter.
  • Gerber LLC sold 10,000 Theravance Biopharma shares in Q1 2025, an estimated $94.1K.
  • Gerber LLC first reported a position in Theravance Biopharma in Q4 2023 and held it in 5 quarters.
  • Gerber LLC's Theravance Biopharma position peaked at $112K in Q4 2023.
  • 131 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2025.

Based on Gerber LLC's 13F filing for Q1 2025, filed 23 Apr 2025.